Myopia is a global visual impairment, and its pathological mechanism involves the complex multifactorial interplay of neurotransmitters, hormones and intracellular signaling pathways. Dopamine inhibits axial growth by activating D2 receptor-CAMP pathway, while GABA energy signals maintain refractive stability by regulating retinal excitation-inhibition balance. Sex hormones and vitamin D play a dual role by regulating scleral ECM metabolism, the former enhances corneal strength and may promote axial elongation during puberty, while the latter exhibits dose-dependent biphasic effects on collagen synthesis via VDR signaling. In the core signaling pathway, the hypoxia-HIF-1α-MMP-2 axis drives sclera ECM degradation, while TGF-β and Wnt/β-catenin pathways synergically regulate fibroblast proliferation and migration. In response to these mechanisms, multi-target intervention strategies show potential: low-dose atropine combined with outdoor light can synergically inhibit axial growth. However, while emerging technologies like gene editing (e.g., CRISPR targeting HIF-1α) and targeted MMP-2 inhibitors are entering preclinical validation, their clinical translation faces substantial hurdles. For CRISPR-based approaches, critical challenges include mitigating off-target editing risks and developing safe, efficient delivery systems to the relevant ocular tissues. Future studies need to integrate molecular mechanisms and interdisciplinary approaches to rigorously evaluate efficacy, safety, and feasibility in order to develop precise prevention and control programs to cope with the epidemic trend of myopia.